{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-positive+Colorectal+Cancer", "query": { "condition": "HER2-positive Colorectal Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-positive+Colorectal+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T23:20:03.629Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07318805", "title": "A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Cancer", "Metastatic Breast Cancer (HR+/ HER2-)", "Colorectal Cancer", "Metastatic Colorectal Adenocarcinoma", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "PF-08032562", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2025-12-23", "completion_date": "2030-04-14", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-05-21T23:20:03.629Z", "location_count": 9, "location_summary": "Duarte, California • Grand Rapids, Michigan • Conroe, Texas + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07318805" }, { "nct_id": "NCT04278144", "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Solid Tumors", "HER2-positive Breast Cancer", "HER2-positive Colorectal Cancer", "HER2-positive Gastroesophageal Cancer", "HER2-positive Endometrial Cancer" ], "interventions": [ { "name": "BDC-1001", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bolt Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2020-02-24", "completion_date": "2025-02-14", "has_results": false, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-05-21T23:20:03.629Z", "location_count": 11, "location_summary": "Palo Alto, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04278144" }, { "nct_id": "NCT07124000", "title": "DESTINY-PANTUMOUR04", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenocarcinoma (NOS)", "Anal Cancer", "Bladder Cancer", "Cervical Cancer", "Endometrial Cancer", "Esophageal Cancer", "Gall Bladder Cancer", "Gastrointestinal Stromal Tumour", "Head and Neck Cancer", "Liver Cancer", "Melanoma", "Mouth Cancer", "Nasopharangeal Cancer", "Neuroendocrine, Gastrointestinal Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Renal Cell Carcinoma", "Salivary Gland Cancer", "Sarcoma", "Small Cell Lung Cancer", "Testicular Cancer", "Throat Cancer", "Thyroid Cancer", "Urethral Cancer", "Vaginal Cancer", "Vulvar Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 100, "start_date": "2025-09-18", "completion_date": "2028-03-30", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-05-21T23:20:03.629Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bullhead City", "state": "Arizona" }, { "city": "Casa Grande", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07124000" }, { "nct_id": "NCT07405476", "title": "Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Carcinoma", "Colorectal Carcinoma", "Rectal Carcinoma", "Stage I Colon Cancer AJCC v8", "Stage I Colorectal Cancer AJCC v8", "Stage I Rectal Cancer AJCC v8", "Stage II Colon Cancer AJCC v8", "Stage II Colorectal Cancer AJCC v8", "Stage II Rectal Cancer AJCC v8", "Stage III Colon Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8" ], "interventions": [ { "name": "Zanidatamab", "type": "BIOLOGICAL" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Endoscopic Procedure", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Digital Rectal Examination", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2026-04-07", "completion_date": "2029-12-18", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-05-21T23:20:03.629Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Decatur, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07405476" }, { "nct_id": "NCT04899908", "title": "Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Cancer", "Brain Metastases", "Melanoma", "Lung Cancer", "Breast Cancer", "HER2-positive Breast Cancer", "Colorectal Cancer", "Gastrointestinal Cancer", "SRS", "SRT", "Whole Brain Radiation", "Stereotactic Radiation", "AGuIX", "Nanoparticle", "Cystic", "Brain Tumor" ], "interventions": [ { "name": "Stereotactic Radiation", "type": "RADIATION" }, { "name": "AGuIX gadolinium-based nanoparticles", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DRUG", "OTHER" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2021-09-15", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-05-21T23:20:03.629Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04899908" }, { "nct_id": "NCT04106167", "title": "Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Advanced Solid Tumor", "Lymphoma", "Gastric Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma", "EGFR Positive Solid Tumor", "HER2-positive Breast Cancer", "Hepatocellular Carcinoma", "Small-cell Lung Cancer", "Renal Cell Carcinoma", "Pancreas Cancer", "Melanoma", "NSCLC", "Urothelial Carcinoma", "Cervical Cancer", "Microsatellite Instability", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "Allogeneic natural killer (NK) cell", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-06-11", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-05-21T23:20:03.629Z", "location_count": 4, "location_summary": "San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04106167" }, { "nct_id": "NCT03602079", "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "HER2 Gene Mutation", "HER-2 Gene Amplification", "HER2 Positive Gastric Cancer", "Salivary Gland Cancer", "Salivary Gland Tumor", "Salivary Gland Carcinoma", "Salivary Gland Neoplasms", "Lung Cancer", "Colo-rectal Cancer", "Rare Diseases", "Solid Tumor", "Recurrent Gastric Cancer", "Recurrent Colon Cancer", "Recurrent Breast Cancer", "Head and Neck Cancer", "Head and Neck Carcinoma", "Bladder Cancer", "Cervical Cancer", "Liver Cancer", "Bile Duct Cancer", "Urologic Cancer", "Pancreatic Cancer", "Prostate Cancer", "Recurrent Prostate Cancer", "Rectal Cancer", "Recurrent Ovarian Carcinoma", "Recurrent Renal Cell Cancer", "Rectal Cancer Stage II", "Rectal Cancer Stage I", "Rectal Cancer Stage III", "Skin Cancer", "Mouth Cancer", "Lip Cancer Stage I", "Tongue Cancer", "Breast Neoplasm Malignant Primary", "Larynx Cancer", "Tonsil Cancer", "Palate Cancer", "Mucoepidermoid Carcinoma", "Primary Peritoneal Carcinoma", "Mucinous Adenocarcinoma Gastric", "Mucinous Breast Cancer Recurrent", "Cholangiocarcinoma" ], "interventions": [ { "name": "A166", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Klus Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-07-16", "completion_date": "2022-01-12", "has_results": false, "last_update_posted_date": "2023-08-03", "last_synced_at": "2026-05-21T23:20:03.629Z", "location_count": 10, "location_summary": "Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03602079" }, { "nct_id": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Carcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Esophageal Adenocarcinoma", "Cholangiocarcinoma", "Gallbladder Carcinoma" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-09-15", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-05-21T23:20:03.629Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04430738" }, { "nct_id": "NCT04704661", "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Carcinoma", "Advanced Colon Carcinoma", "Advanced Colorectal Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Gastric Carcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Salivary Gland Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "HER2-Positive Breast Carcinoma", "Malignant Hepatobiliary Neoplasm", "Metastatic Breast Carcinoma", "Metastatic Colon Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Salivary Gland Carcinoma", "Stage III Colon Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Major Salivary Gland Cancer AJCC v8", "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Major Salivary Gland Cancer AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Unresectable Breast Carcinoma", "Unresectable Colon Carcinoma", "Unresectable Colorectal Carcinoma", "Unresectable Endometrial Carcinoma", "Unresectable Gastric Carcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Salivary Gland Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2021-08-09", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-05-21T23:20:03.629Z", "location_count": 23, "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 16 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04704661" }, { "nct_id": "NCT04172597", "title": "A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Solid Tumor", "Glioblastome Multiforme" ], "interventions": [ { "name": "Poziotinib Hydrochloride", "type": "DRUG" }, { "name": "Loperamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2019-12-23", "completion_date": "2022-03-29", "has_results": true, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-05-21T23:20:03.629Z", "location_count": 1, "location_summary": "Long Beach, California", "locations": [ { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04172597" } ] }